Suraj Fanse is a Senior Scientist at Merck & Co., specializing in the development of Sterile and Specialty Products within the realm of drug product formulation. With a Ph.D. in pharmaceutical sciences, Suraj brings a wealth of knowledge and expertise to the team, particularly in...
Suraj Fanse is a Senior Scientist at Merck & Co., specializing in the development of Sterile and Specialty Products within the realm of drug product formulation. With a Ph.D. in pharmaceutical sciences, Suraj brings a wealth of knowledge and expertise to the team, particularly in the formulation development and analytical characterization of long-acting controlled release drug delivery systems. His current role involves leading key projects that focus on the innovative design and optimization of drug-device combination products, ensuring that they meet stringent regulatory standards while delivering optimal therapeutic outcomes.
Suraj's extensive experience in in vitro drug release testing is instrumental in assessing the performance of various formulations, particularly in the context of Dry Powder Inhalers (DPIs) and aerosol performance. His proficiency in high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC) allows him to conduct thorough analytical characterization of pharmaceutical products, ensuring their quality and efficacy. Suraj's strong foundation in chemometrics further enhances his ability to analyze complex data sets, driving informed decisions in formulation strategies.
At Merck, Suraj is not only committed to advancing drug delivery technologies but also to fostering a culture of compliance with Good Manufacturing Practices (GMP). His collaborative approach and passion for pharmaceutics position him as a key contributor to the development of specialty products that address unmet medical needs. Through his work, Suraj is dedicated to pushing the boundaries of pharmaceutical innovation, ultimately improving patient outcomes and enhancing the quality of life for individuals relying on these critical therapies.
